Latest news with #AS
Yahoo
5 days ago
- Sport
- Yahoo
Xabi Alonso seriously considering starting Real Madrid youngster vs Al-Hilal
Real Madrid will play their first game of the Xabi Alonso era later tonight as they take on Al-Hilal in their first Group H game of the 2025 FIFA Club World Cup in the USA. All eyes will be on the new manager as fans eagerly await to see how he sets up the team and the starting lineup he picks for his first game in charge. Advertisement The defensive side of things seem pretty much settled with both new signings Trent Alexander-Arnold and Dean Huijsen expected to start alongside Raul Asencio and Fran Garcia. The likes of Federico Valverde, Jude Bellingham, and Aurelien Tchouameni are the leading candidates to start in midfield. Kylian Mbappe's possible absence in attack due to a fever has opened up a spot in attack. Arda Guler to start? As such, AS now reports that manager Xabi Alonso is seriously considering handing a start to Arda Guler on the right flank tonight against Al-Hilal. Alonso believes in Guler. (Photo by) Advertisement With Mbappe out, Rodrygo is expected to feature at centre-forward while Vinicius Jr. will keep his place on the left. And, Guler could now be a strong candidate to take the final spot in the Real Madrid frontline tonight. It is no secret that Guler is a player Alonso admires greatly. Bayer Leverkusen have attempted to secure him on loan for the past two summers, but the youngster had closed the door firmly. During their first days working together since June 9, Alonso has taken a very close interest in the youngster. In yesterday's training session, during the 15 minutes open to the press, he was seen giving specific instructions to the Turkish prodigy. It could be a strong indicator that Guler is in line for a starting berth tonight when Real Madrid take on Al-Hilal in their Club World Cup opener. A gifted talent, Guler was unable to nail down a spot for himself in the team under Carlo Ancelotti. But he will hope that things are different with Alonso.
Yahoo
12-06-2025
- Business
- Yahoo
Ionis doses first subject in Phase III trial of Angelman syndrome therapy
Ionis Pharmaceuticals has dosed the first subject in the global, randomised Phase III REVEAL trial of investigational ION582, aimed at treating individuals with Angelman syndrome (AS), a rare neurodevelopmental disorder. The placebo-controlled, double-blind trial will recruit nearly 200 AS adults and children with a maternal UBE3A gene deletion or mutation. Over a 52-week treatment period, subjects will be randomised in a 2:1 ratio and given either the therapy or a placebo. Quarterly doses of either 40mg or 80mg of ION582 will be administered to those in the active treatment groups. After the initial treatment phase, eligible subjects will have the opportunity to enter a long-term extension segment of the trial, where the therapy will be administered for up to two years. The primary goal of the trial is to assess improvements in expressive communication using the Bayley Scales for Infant and Toddler Development-4 (Bayley-4), a direct clinician-administered assessment tool. Expressive communication deficits are notably the most burdensome symptoms for caregivers of individuals with AS. The trial will also evaluate secondary endpoints, including overall disease severity, communication, cognition, motor functioning, sleep, and daily living skills, as well as other exploratory endpoints. ION582 has previously shown promise in the multiple ascending dose (MAD) portion of the Phase I/II open-label HALOS trial, demonstrating clinical improvement across various functional domains such as cognition, motor function, and communication. The RNA-targeted antisense medicine, ION582, works by inhibiting the expression of the UBE3A antisense transcript (UBE3A-ATS) to potentially increase the UBE3A protein production, to treat AS. Ionis Pharmaceuticals neurology senior vice-president Holly Kordasiewicz: 'This placebo-controlled study will evaluate ION582 in both children and adults with either UBE3A deletion or mutation and builds on earlier encouraging findings from our Phase I/II HALOS study. 'With ION582, we continue to advance our leading wholly owned neurology pipeline, which includes eight medicines in clinical development across a range of rare and more prevalent diseases.' Last year, Ionis announced the design for the Phase III trial of ION582 for the treatment of AS, following discussions with the US Food and Drug Administration. "Ionis doses first subject in Phase III trial of Angelman syndrome therapy" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
11-06-2025
- Business
- Business Wire
First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome
CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the global Phase 3 REVEAL study, which is designed to evaluate the efficacy and safety of ION582, an investigational medicine for the treatment of people living with Angelman syndrome (AS), a serious and rare neurodevelopmental disorder that leads to significant physical and cognitive impairments. 'Dosing the first person with Angelman syndrome in our pivotal REVEAL study marks an important milestone for this underserved community, who currently have no approved disease modifying treatments,' said Holly Kordasiewicz, Ph.D., senior vice president of neurology, Ionis. 'This placebo-controlled study will evaluate ION582 in both children and adults with either UBE3A deletion or mutation and builds on earlier encouraging findings from our Phase 1/2 HALOS study. This milestone reflects our commitment to those impacted by Angelman syndrome and builds on our legacy of innovation in neurology including the development of SPINRAZA and QALSODY. With ION582, we continue to advance our leading wholly owned neurology pipeline, which includes eight medicines in clinical development across a range of rare and more prevalent diseases.' REVEAL (NCT06914609) is a global, randomized, double-blind, placebo-controlled Phase 3 study that will enroll approximately 200 children and adults with AS that have a maternal UBE3A gene deletion or mutation. During the 52-week treatment period, participants will be randomized 2:1 to receive either ION582 or placebo. Participants in the active treatment groups will receive quarterly 40 mg or 80 mg doses of ION582. Following the treatment period, eligible participants will transition into the long-term extension portion of the study where all participants will receive ION582 for up to 2 years. The primary endpoint is improvement in expressive communication as assessed by the Bayley Scales for Infant and Toddler Development-4 (Bayley-4), an objective and direct clinician-administered assessment of clinical functioning. Deficits in expressive communication are reported to be the symptoms most challenging to caregivers of people with AS. Secondary endpoints include overall disease severity, cognition, communication, sleep, motor functioning and daily living skills, in addition to other exploratory endpoints. In the completed multiple ascending dose (MAD) portion of the Phase 1/2 open-label HALOS study, ION582 provided consistent and encouraging clinical improvement on all functional domains including communication, cognition and motor function and showed favorable safety and tolerability at all dose levels in the study. For more information on the REVEAL clinical study, please visit and About ION582 ION582 is an investigational RNA-targeted antisense medicine designed to inhibit the expression of the UBE3A antisense transcript (UBE3A-ATS) and increase production of UBE3A protein, for the potential treatment of Angelman syndrome (AS). The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) granted Orphan Drug designation to ION582. Additionally, the FDA granted Fast Track and Rare Pediatric designations to ION582. About Angelman Syndrome (AS) AS is a rare, genetic neurological disease that affects an estimated 1 in 21,000 people worldwide and is caused by the loss of function of the maternally inherited UBE3A gene. AS typically presents in infancy and is characterized by profound intellectual disability, balance issues, motor impairment and debilitating seizures. Most people with AS are unable to speak. Individuals with AS have a normal lifespan but require complete care from a caregiver. Some symptoms can be managed with existing medicines; however, there are no approved disease modifying therapies. About Ionis Neurology Ionis has been at the forefront of discovering and developing leading neurological disease medicines, including SPINRAZA ® (nusinersen), the first approved treatment for spinal muscular atrophy, WAINUA™ (eplontersen), a medicine to treat hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN), and QALSODY ® (tofersen) for SOD1-ALS. The clinical-stage portfolio includes 13 therapies, of which eight are wholly owned by Ionis. Ionis' investigational portfolio includes medicines for which there are few or no disease modifying treatments, such as rare diseases including Prion disease and Alexander disease and more common conditions such as Alzheimer's and Parkinson's disease. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has six marketed medicines and a leading pipeline in neurology, cardiology, and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit and follow us on X (Twitter), LinkedIn and Instagram. Ionis Forward-looking Statements This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of ION582, our commercial medicines, additional medicines in development and technologies. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2024, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company. In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our" and "us" all refer to Ionis Pharmaceuticals and its subsidiaries. Ionis Pharmaceuticals ® is a trademark of Ionis Pharmaceuticals, Inc. SPINRAZA ® and QALSODY ® are registered trademarks of Biogen. WAINUA™ is a registered trademark of the AstraZeneca group of companies.
New York Post
09-06-2025
- Health
- New York Post
Do you have an ‘office chair butt'? Here's what workers who ‘refuse to fall victim' are doing about it
What's droopy, floppy and sagging around the office? No, it's not your crabby boss — it's your flabby butt. Sitting on one's backside for hours on end, slouched in a seat while staring at a computer screen, is flattening once-rounded heinies. 'I refuse to fall victim,' swore Krystina, a NYC-based content creator, warding off the wicked woes of 'office chair butt.' Advertisement 4 Folks online are worried about contracting the dreaded 'office chair butt' while on their jobs. Andrey Popov – Despite its social media-given nickname, the aforementioned curse is a legitimate plague on patooties — more formally known as atrophy of the gluteal muscle group — caused by chronic sitting, according to the Cleveland Clinic. And yes, it's as bad for your booty as it sounds. Advertisement 'A lack of conditioning in your gluteus maximus and surrounding tissue leads to weakness, making it build up fat tissue and appear flatter or saggy,' explained Michael Milicia, an occupational therapist, in a recent report for the clinic. The doc noted that the actual chair a hireling sits in is not to blame for his or her beleaguered bottom. Instead, the true culprit is their lack of movement while on the clock. 'Sitting too long without breaks isn't particularly good for anything,' Milicia said. Advertisement And his butt advisory is right on the nose. Researchers from Beijing, China, recently reconfirmed the cautionary adage, 'sitting is the new smoking,' finding that employees — namely office workers — are at a high risk of experiencing severe neck pain. 4 Investigators have found that sitting for long periods of time can trigger body aches and neck pains. Kittiphan – Kristianne Egbert, a board-certified professional ergonomist, issued a similar warning to The Post, saying, 'holding any one posture for an extended period — whether sitting or standing — can take a toll on your body.' Advertisement 'Static positions cause muscles to tense, slow blood flow and lead to fatigue,' she added. Still, most 9-to-5ers, especially those who've been called to return the office for long-stretch shifts, are forced to park their hind parts in uncomfortable chairs in cramped cubicles for at least five days per week. 4 Experts warn that constant sitting can cause one's buns to become flabby, saggy, flat and squishy. AS/ – The bootylicious online, however, are working their butts to the bone with mid-day exercises, hoping the avoid the ills of office chair atrophy. 'Me every 30 minutes when I find out what office chair butt is,' Haike, a TikTok user, wrote in the closed-captions of a clip that featured her doing knee-lifts at her desk, running up and down a flight of stairs and doing laps around a conference room in her workplace. Loba, an internet influencer from Chicago, stepped away from her workspace to hit a series of squats after catching a shocking glimpse of her flap-jack fanny. And Nikki, a well-endowed diva, lead her team of fellow employees, comprised of both men and women, in executing several repetitions of lunges, squats, leg-lifts and stair climbs, vowing in her vid, 'No office chair butt for us.' Advertisement 4 Squats, leg exercises and butt clenches are all recommended for counteracting the flattening effects of office chair butt, per Cleveland Clinic. T Mdlungu/ – For a Beyonce-like behind, Milica recommends slaying those exercises and more every day, suggesting folks, 'get up and move every 30 to 90 minutes, as your job allows.' Here are a few derrière-improving workouts to help you avoid looking like you've got pancakes in your work pants. Standing while taking a phone call Placing your filing cabinet or other equipment you use during the day a few feet away from your desk Walking to a colleague's office for a face-to-face talk, rather than sending an email Inviting co-workers for a walking meeting Taking the stairs rather than the elevator Choosing a restroom that's a little farther away Switching to a sit-stand desk Try a walking pad under your desk Butt clenches Marching in place Heel lifts Toe lifts Ankle circles Squeezing a ball (or your fists or other prop) between your legs Trying to hold your knees apart while pushing them together when your hands
Morocco World
09-06-2025
- Sport
- Morocco World
Ouazane Set to Join Real Madrid After Rejecting Ajax
Abdellah Ouazane is reportedly on the brink of a move to Real Madrid after he rejected multiple contract offers from Ajax, with his current deal set to expire on June 30. The highly-rated 16-year-old midfielder is widely regarded as one of Ajax's greatest talents and has reportedly turned down up to three offers, including a final attempt to tie him down to a professional contract. AS sources indicate that the situation now looks grim for the Amsterdam club, as hopes of keeping him are fading fast. The deal to bring Ouazane to Madrid is described as 'virtually a done deal'. Ajax's failure to secure Ouazane's signature earlier this year has left the club scrambling. The midfielder did not sign a professional contract despite turning 16 in January. This delay now appears to have cost Ajax their star player, with Madrid set to sign him on a free transfer. Ouazane's versatility and impressive performances at the youth level have made him one of the most exciting and coveted young talents in European football. He was named MVP of the U17 Africa Cup of Nations, where he dazzled as a central midfielder, attacking midfielder, and playmaker. His dribbling skills, powerful right foot, and football intelligence have drawn comparisons to Jude Bellingham. At 1.83 meters tall, Ouazane combines physicality with technical brilliance, making him a perfect fit for Madrid's ambitious youth project. If confirmed, the move will add another promising player to the club's growing list of young stars alongside Endrick, Arda Guler, Joan Martínez and Jacobo Ramón. Tags: AjaxOuazaneReal Madrid
